Tumor Markers in Lung Cancer: Current Progress, Role in Targeted Therapy and Further Direction
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (4 January 2024) | Viewed by 1646
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lung cancer is one of the leading cancer-related causes of death worldwide. The five-year survival rate of patients is around 50% without metastasis, while only about 5% of patients with distant tumors survive. Other than personal living habits, early diagnosis and proper treatment highly affect the quality of life of patients. Effective biomarkers could provide novel therapeutic opportunities, targeting therapy, immunotherapy, etc., that could significantly prolong the outcomes of patients. For example, overexpressed PD-L1 on the tumor surface is associated with metastasis of tumor cells, which leads to the development of anti-PD-L1 monoclonal antibodies or vaccines that block PD-1/PD-L1 signaling. For this Special Issue, papers discussing any biomarkers related to lung cancer, circulating tumor cells, tumor-free DNA, circulating miRNAs, small molecules, cytokines, checkpoint markers, PD-L1, exosomes, and so on are welcome.
This Special Issue will focus on publishing high-quality works related to the biomarkers for the early diagnosis of lung cancer, prediction of treatment resistance, and prevention of the recurrence of tumors that might raise and promote novel diagnostic and/or therapeutic strategies for daily clinical practice to benefit patients.
Prof. Dr. Qing Kay Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- NSCLC
- SCLC
- biomarker
- early screening
- diagnosis
- PD-1/PD-L1
